Sensitive PCR Test Detects Early Stage Lyme Disease
By LabMedica International staff writers Posted on 19 Apr 2021 |
Image: Darkfield photomicrograph (magnified 400x) showing the presence of the spirochaete Borrelia burgdorferi, which is the pathogen that causes Lyme disease (Photo courtesy of [U.S.] Centers for Disease Control and Prevention via Wikimedia Commons)
A highly sensitive blood test detects the bacteria that causes Lyme disease in early stages of the infection, when treatment can prevent the development of serious or fatal consequences of the chronic disease.
The successful treatment of Lyme disease (LD) is contingent on accurate diagnosis. However, current laboratory detection assays lack sensitivity in the early stages of the disease. Since delayed diagnosis of LD can result in high healthcare costs and great suffering to the patient, new highly sensitive tests are needed.
In this regard, investigators at the University of Leicester (United Kingdom) developed an internally controlled quantitative PCR test that targeted the multicopy terminase large subunit (terL) gene encoded by prophages that are only found in LD-causing bacteria. A prophage is a bacteriophage genome inserted and integrated into the circular bacterial DNA chromosome or present as an extrachromosomal plasmid. This is a latent form of a phage, in which the viral genes are present in the bacterium without causing disruption of the bacterial cell.
The newly developed Ter-qPCR test was based on the polymerase chain reaction (PCR), which amplifies small amounts of specific genetic material so that it can be detected. To increase the sensitivity of the test for detection of Borrelia burgdorferi, the causative agents of Lyme disease, the investigators adapted it to be specific for the prophage terL gene. The terL protein helps phages package their DNA.
The diagnostic potential of the Ter-qPCR test was evaluated using a set of blood and serum samples collected from healthy volunteers and individuals who were clinically diagnosed with Lyme disease. Results revealed that the detection limit of the Ter-qPCR test was estimated to be 22 copies, the equivalent of one bacterial cell in a bacteria spiked blood sample. Furthermore, significant quantitative differences were observed in terms of the amount of terL detected in healthy individuals and patients with either early or late Lyme disease.
"Early diagnosis of Lyme disease is absolutely vital in reducing suffering, because early Lyme can be treated, but late Lyme is very difficult to treat," said first author Dr. Jinyu Shan, a researcher in the department of respiratory sciences at the University of Leicester. "Current tests cannot typically detect the low numbers of bacteria in early-stage patient blood samples. Our goal was to design a highly sensitive test to help doctors to identify Lyme disease as early as possible. We are currently working with a commercial partner, and investigating regulatory issues and the potential for a clinical trial for this technology."
The Ter-qPCR test was described in the March 15, 2021, online edition of the journal Frontiers in Microbiology.
Related Links:
University of Leicester
The successful treatment of Lyme disease (LD) is contingent on accurate diagnosis. However, current laboratory detection assays lack sensitivity in the early stages of the disease. Since delayed diagnosis of LD can result in high healthcare costs and great suffering to the patient, new highly sensitive tests are needed.
In this regard, investigators at the University of Leicester (United Kingdom) developed an internally controlled quantitative PCR test that targeted the multicopy terminase large subunit (terL) gene encoded by prophages that are only found in LD-causing bacteria. A prophage is a bacteriophage genome inserted and integrated into the circular bacterial DNA chromosome or present as an extrachromosomal plasmid. This is a latent form of a phage, in which the viral genes are present in the bacterium without causing disruption of the bacterial cell.
The newly developed Ter-qPCR test was based on the polymerase chain reaction (PCR), which amplifies small amounts of specific genetic material so that it can be detected. To increase the sensitivity of the test for detection of Borrelia burgdorferi, the causative agents of Lyme disease, the investigators adapted it to be specific for the prophage terL gene. The terL protein helps phages package their DNA.
The diagnostic potential of the Ter-qPCR test was evaluated using a set of blood and serum samples collected from healthy volunteers and individuals who were clinically diagnosed with Lyme disease. Results revealed that the detection limit of the Ter-qPCR test was estimated to be 22 copies, the equivalent of one bacterial cell in a bacteria spiked blood sample. Furthermore, significant quantitative differences were observed in terms of the amount of terL detected in healthy individuals and patients with either early or late Lyme disease.
"Early diagnosis of Lyme disease is absolutely vital in reducing suffering, because early Lyme can be treated, but late Lyme is very difficult to treat," said first author Dr. Jinyu Shan, a researcher in the department of respiratory sciences at the University of Leicester. "Current tests cannot typically detect the low numbers of bacteria in early-stage patient blood samples. Our goal was to design a highly sensitive test to help doctors to identify Lyme disease as early as possible. We are currently working with a commercial partner, and investigating regulatory issues and the potential for a clinical trial for this technology."
The Ter-qPCR test was described in the March 15, 2021, online edition of the journal Frontiers in Microbiology.
Related Links:
University of Leicester
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders